Central Illustration: Acellular Biomaterial Therapeutics for Repairing Ischemic Damage From MI and PAD

2019-06-11T07:04:10Z (GMT) by Melissa J. Hernandez Karen L. Christman
Preclinical studies have currently been investigating biomaterial-alone therapies or biomaterials loaded with therapeutics as potential treatment options for myocardial infarction (MI) and peripheral artery disease (PAD). Other therapeutics, like microribonucleic acids (miRNAs) or exosomes, also show promise as factors to be delivered with a biomaterial. However, the success of these therapies largely depends on satisfying specific design criteria.